Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection

Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection

Bibliographic Details
Main Authors: Amin, Janaki, Boyd, Mark A., Kumarasamy, Nagalingeswaran, Moore, Cecilia L., Losso, Marcello H., Nwizu, Chidi A., Mohapi, Lerato, Kerr, Stephen J., Sohn, Annette H., Teppler, Hedy, Renjifo, Boris, Molina, Jean-Michel, Emery, Sean, Cooper, David A.
Format: Online
Language:English
Published: Public Library of Science 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344344/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344344/

Similar Items